Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6‐year prospective study
Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 2232-2241
DOI: 10.1111/dom.16224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.02.2025. Verfasst von Dan Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Fibroblast Growth Factors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovative Research Team of High-level Local Universities in Shanghai, Excellent Young Scientists Fund of NSFC, General Fund of NSFC.
Abstract (Originalsprache)
Aims
Fibroblast growth factor (FGF) 23 is a bone‐derived phosphaturic hormone that participates in the regulation of mineral metabolism and the development of chronic kidney disease. This study aimed to investigate the association between FGF23 and diabetic kidney disease (DKD) in a community‐based prospective cohort. Materials and Methods Of 7230 individuals who completed a 4.6‐year follow‐up survey, 1614 individuals with diabetes at baseline were included in this study. Baseline serum FGF23 levels were measured by enzyme‐linked immunosorbent assay. Multiple and ordinal logistic regression analyses were used to examine the predictive performance of baseline FGF23 for incident DKD.
Results
Baseline serum FGF23 levels exhibited an earlier elevation in the course of DKD and a gradual increase with the progressive stages of DKD ( p < 0.05), while no statistical changes were observed in serum calcium and phosphorus levels. Over a 4.6‐year follow‐up, 198 individuals with diabetes developed incident DKD. Baseline FGF23 was significantly associated with the incidence of DKD (odds ratio 1.290 [95% CI 1.063, 1.565]) after adjusting for conventional DKD risk factors, especially in individuals with lower body mass index (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai K…
- Department of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Shufei Zang, Weiping Jia, Huating Li
Förderung
- Innovative Research Team of High-level Local Universities in Shanghai
- Excellent Young Scientists Fund of NSFC
- General Fund of NSFC
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Municipal Key Clinical Specialty
- Shanghai Research Center for Endocrine and Metabolic Diseases
- Shanghai Pujiang Program
Zitieren
APA
Liu, D., Yu, S., Zhang, Y., Li, Q., Kang, P., Wang, L., Han, R., Cheng, D., Chen, A., Hou, X., Wu, L., Zang, S., Fang, Q., Jia, W., & Li, H. (2025). Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6‐year prospective study. Diabetes, Obesity and Metabolism, 27(4), 2232-2241. https://doi.org/10.1111/dom.16224
Vancouver
Liu D, Yu S, Zhang Y, Li Q, Kang P, Wang L, et al. Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6‐year prospective study. Diabetes, Obesity and Metabolism. 2025;27(4):2232-2241. doi:10.1111/dom.16224
BibTeX
@article{Liu2025,
author = {Liu, Dan and Yu, Shujie and Zhang, Ying and Li, Qian and Kang, Piao and Wang, Lihong and Han, Rui and Cheng, Di and Chen, Anran and Hou, Xuhong and Wu, Liang and Zang, Shufei and Fang, Qichen and Jia, Weiping and Li, Huating},
title = {Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6‐year prospective study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {4},
pages = {2232--2241},
doi = {10.1111/dom.16224}
}
EUVIMED